US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Veraxa Biotech Holding AG

1.95

+0.06003.17%

Post-market: 1.950.00000.00%19:02 EDT

Volume:80.15K

Turnover:155.63K

Market Cap:275.75M

PE:9.10

High:2.00

Open:1.86

Low:1.85

Close:1.89

52wk High:27.36

52wk Low:1.70

Shares:141.41M

Float Shares:41.01M

Volume Ratio:0.97

T/O Rate:0.20%

Dividend:- -

Dividend Rate:- -

EPS(TTM):0.2142

ROE:-65.29%

ROA:-20.46%

PB:7.11

PE(LYR):- -

Loading ...

Overview Company News Filings

Veraxa Biotech Files Form 3 for Interim CFO Carl Von Halem

VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies

Veraxa Biotech Holding Ag - Files to Register Resale of up to 25 Mln Ordinary Shares - SEC Filing

THOMSON REUTERS

Veraxa Biotech Files First BiTAC-related Patent Applications for Cancer Therapy Platforms

VERAXA Biotech (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform

Veraxa Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates

THOMSON REUTERS

VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates

VERAXA Biotech (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures

VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration

Veraxa Biotech advances VXA-222 following milestone in OmniAb pact

Veraxa Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program Vxa-222 from Joint Discovery Collaboration with OmniAb

THOMSON REUTERS

Veraxa Biotech Shareholders Approved All Proposals at Extraordinary General Meeting

Veraxa Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth

THOMSON REUTERS

VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer

VERAXA Biotech (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany

Veraxa Biotech Names Christoph Erkel Chief Scientific Officer, Succeeding Rick Austin

Veraxa Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance Bitac® Technology Platforms and Portfolio

THOMSON REUTERS

Veraxa Biotech Receives PEI Scientific Advice on Bitac-tce Development Plan

Veraxa Biotech Announces Regulatory Progress with Its Bitac®-tce Development Plan

THOMSON REUTERS

VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/VRXA/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"VRXA","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","market":"US","secType":"STK","nameCN":"Veraxa Biotech Holding AG","latestPrice":1.95,"timestamp":1787342400000,"preClose":1.89,"halted":0,"volume":80147,"hourTrading":{"tag":"盘后","latestPrice":1.95,"preClose":1.95,"latestTime":"19:02 EDT","volume":146,"amount":283.17,"timestamp":1787353358074,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":0.03174603174603178,"floatShares":41012504,"shares":141407813,"eps":0.2142,"marketStatus":"Market Closed","change":0.06,"latestTime":"08-21 16:00:00 EDT","open":1.86,"high":2,"low":1.8501,"amount":155628,"amplitude":0.079312,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":0.2142,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1787558400000},"marketStatusCode":7,"adr":0,"exchange":"NASDAQ","adjPreClose":1.89,"preHourTrading":{"tag":"盘前","latestPrice":1.87,"preClose":1.89,"latestTime":"09:27 EDT","volume":304,"amount":569.2840192,"timestamp":1787318870054,"change":-0.02,"changeRate":-0.010582,"amplitude":0.015873},"postHourTrading":{"tag":"盘后","latestPrice":1.95,"preClose":1.95,"latestTime":"19:02 EDT","volume":146,"amount":283.17,"timestamp":1787353358074,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.967295187072036},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"VRXA\",,,,,undefined,":{"symbol":"VRXA","floatShares":41012504,"roa":"-20.46%","roe":"-65.29%","lyrEps":0,"volumeRatio":0.967295187072036,"shares":141407813,"dividePrice":0,"high":2,"amplitude":0.079312,"preClose":1.89,"low":1.8501,"week52Low":1.7,"pbRate":"7.11","week52High":27.36,"institutionHeld":0,"latestPrice":1.95,"eps":0.2142,"divideRate":0,"volume":80147,"delay":0,"ttmEps":0.2142,"open":1.86,"prevYearClose":18.65,"prevWeekClose":1.87,"prevMonthClose":1.76,"prevQuarterClose":1.88,"fiveDayClose":1.87,"twentyDayClose":1.8},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/VRXA\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"VRXA\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"VRXA\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/VRXA\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"VRXA","date":"2026-08-21","current":9.103641,"percent":0,"low":-1.35335,"twenty":-1.349054,"median":-1.34261,"eighty":-1.336165,"high":-1.331869,"avg":-1.34261,"sd":0.010741,"marketCap":47660725},"quantilePoints":[{"date":"2026-08-21","current":-1.35335,"twenty":-1.349054,"median":-1.34261,"eighty":-1.336165,"marketCap":47660725}],"updateTime":1787529336911},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"VRXA\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2661234428","title":"Veraxa Biotech Files Form 3 for Interim CFO Carl Von Halem","url":"https://stock-news.laohu8.com/highlight/detail?id=2661234428","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661234428?lang=en_us&edition=fundamental","pubTime":"2026-08-21 04:00","pubTimestamp":1787256059,"startTime":"0","endTime":"0","summary":"Veraxa Biotech files Form 3 for Interim CFO Carl von HalemInterim CFO Carl von Halem filed an initial Form 3 for Veraxa Biotech AG, dated July 10, 2026.Disclaimer:This news brief was created by Public","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260820:nNDL7C4F43:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657656766","title":"VERAXA Biotech (NASDAQ: VRXA) Advances VXA-222 Cancer Program While Expanding Patent Portfolio for Next-Generation Antibody Technologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2657656766","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657656766?lang=en_us&edition=fundamental","pubTime":"2026-08-07 01:00","pubTimestamp":1786035614,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, August 6th, 2026, FinanceWire The company has advanced its VXA-222 bispecific antibody-drug conjugate (“bsADC&r...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-vxa-222-cancer-program-while-expanding-patent-portfolio-for-next-generation-antibody-technologies?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-vxa-222-cancer-program-while-expanding-patent-portfolio-for-next-generation-antibody-technologies?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","QQQM","QQQA","QQQJ","VRXA","BK4585","SQQQ","GPIQ","JEPQ","XBI","QDTE","ONEQ","QQQ","TQQQ","QYLG","QQQY","NVIW.SI","TQQY","BK4581","IYW",".IXIC","QID","FTEC","BK4588","QQQE","TECS","NDX","MNQmain","NQmain","QLD","PSQ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656917923","title":"Veraxa Biotech Holding Ag - Files to Register Resale of up to 25 Mln Ordinary Shares - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2656917923","media":"THOMSON REUTERS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656917923?lang=en_us&edition=fundamental","pubTime":"2026-08-01 05:14","pubTimestamp":1785532463,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nFWN43X2AR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656399655","title":"Veraxa Biotech Files First BiTAC-related Patent Applications for Cancer Therapy Platforms","url":"https://stock-news.laohu8.com/highlight/detail?id=2656399655","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656399655?lang=en_us&edition=fundamental","pubTime":"2026-08-01 04:06","pubTimestamp":1785528362,"startTime":"0","endTime":"0","summary":"Veraxa Biotech files first BiTAC-related patent applications for cancer therapy platformsVeraxa Biotech filed its first BiTAC-related patent applications in H1 2026 covering composition of matter for ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260731:nNDL5xBfbf:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655807507","title":"VERAXA Biotech (NASDAQ: VRXA) Strengthens Scientific Leadership as New CSO Takes the Helm in Advancing BiTAC(R) Cancer Therapy Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2655807507","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655807507?lang=en_us&edition=fundamental","pubTime":"2026-07-31 01:30","pubTimestamp":1785432641,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, July 30th, 2026, FinanceWire The company has appointed antibody therapeutics specialist Dr. Christoph Erkel as Chief ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-strengthens-scientific-leadership-as-new-cso-takes-the-helm-in-advancing-bitacr-cancer-therapy-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-strengthens-scientific-leadership-as-new-cso-takes-the-helm-in-advancing-bitacr-cancer-therapy-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["PSQ","VRXA","QDTE","QLD","XBI","TECS","SQQQ","TQQY","TQQQ","QQQE","QQQY","QID","BK4585","QQQA","NVIW.SI","BK4588","NQmain","QQQ","GPIQ","MNQmain","BK4022","R","FTEC","JEPQ","NDX","ONEQ","BK4139","QQQJ","BK4581","QYLG","BK4232","QQQM","IYW",".IXIC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655861707","title":"Veraxa Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2655861707","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655861707?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:00","pubTimestamp":1785322800,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260729:nTUABGQ6NH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655686238","title":"VERAXA Biotech Strengthens Patent Portfolio to Protect Core Technology Platforms and Product Candidates","url":"https://stock-news.laohu8.com/highlight/detail?id=2655686238","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655686238?lang=en_us&edition=fundamental","pubTime":"2026-07-29 19:00","pubTimestamp":1785322800,"startTime":"0","endTime":"0","summary":"First BiTAC-related patent applications filed in H1 2026 including patents covering composition of matter and proprietary payload platform, with additional patents secured in contributing technology a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/29/3335104/0/en/VERAXA-Biotech-Strengthens-Patent-Portfolio-to-Protect-Core-Technology-Platforms-and-Product-Candidates.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4139","BK4588","BK4231","BK4080","XBI","BK4585","VRXA","ADC","NETL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655446889","title":"VERAXA Biotech (NASDAQ: VRXA) Shareholders Approve Corporate Governance, Financing Measures","url":"https://stock-news.laohu8.com/highlight/detail?id=2655446889","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655446889?lang=en_us&edition=fundamental","pubTime":"2026-07-29 01:00","pubTimestamp":1785258032,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, July 28th, 2026, FinanceWire VERAXA Biotech (NASDAQ:VRXA) announced that shareholders overwhelmingly approv...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-shareholders-approve-corporate-governance-financing-measures?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-shareholders-approve-corporate-governance-financing-measures?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MNQmain","IYW","QID","QQQE","FTEC","QDTE","BK4588","SQQQ","TQQQ","PSQ","ONEQ","NQmain",".IXIC","QLD","NVIW.SI","VRXA","NDX","JEPQ","QQQJ","QQQM","TECS","QQQ","BK4581","BK4585","GPIQ","TQQY","QQQA","XBI","QQQY","QYLG","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654047585","title":"VERAXA Biotech (NASDAQ: VRXA) Advances Bispecific ADC Program Under OmniAb Collaboration","url":"https://stock-news.laohu8.com/highlight/detail?id=2654047585","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654047585?lang=en_us&edition=fundamental","pubTime":"2026-07-28 02:30","pubTimestamp":1785177027,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, July 27th, 2026, FinanceWire VERAXA Biotech (NASDAQ:VRXA) announced the advancement of its bispecific antibody-d...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-bispecific-adc-program-under-omniab-collaboration?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-bispecific-adc-program-under-omniab-collaboration?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QQQE","JEPQ","BK4231","GPIQ","NVIW.SI","QLD","NQmain","QQQJ","XBI","NETL","BK4581","BK4588","TQQQ","QQQM","TECS",".IXIC","TQQY","BK4080","QQQ","NDX","VRXA","QQQA","BK4585","PSQ","ADC","SQQQ","BK4139","FTEC","MNQmain","QQQY","ONEQ","QID","QDTE","IYW","QYLG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654140440","title":"Veraxa Biotech advances VXA-222 following milestone in OmniAb pact","url":"https://stock-news.laohu8.com/highlight/detail?id=2654140440","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654140440?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:20","pubTimestamp":1785151247,"startTime":"0","endTime":"0","summary":"Veraxa Biotech (VRXA) announced the advancement of bispecific ADC program VXA-222, following successful achievement of a key technical milestone in...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/veraxa-biotech-advances-vxa-222-following-milestone-in-omniab-pact-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/veraxa-biotech-advances-vxa-222-following-milestone-in-omniab-pact-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4139","BK4581","XBI","VRXA","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654901487","title":"Veraxa Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program Vxa-222 from Joint Discovery Collaboration with OmniAb","url":"https://stock-news.laohu8.com/highlight/detail?id=2654901487","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654901487?lang=en_us&edition=fundamental","pubTime":"2026-07-27 19:00","pubTimestamp":1785150000,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260727:nTUA8QKY0T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","VRXA"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654032636","title":"Veraxa Biotech Shareholders Approved All Proposals at Extraordinary General Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2654032636","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654032636?lang=en_us&edition=fundamental","pubTime":"2026-07-25 04:05","pubTimestamp":1784923546,"startTime":"0","endTime":"0","summary":"Veraxa Biotech shareholders approved all proposals at extraordinary general meetingVeraxa held an extraordinary general meeting today.Shareholders adopted all board proposals.Approved amendments intro","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDL4hXVm8:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2T93.GBP","BK4112","IE00BGHQF748.EUR","IE00B64PRP62.GBP","BK4585","BCDF","IE00BN0W2V16.EUR","IE00BN0W2W23.USD","LU0314104364.USD","VRXA","SG9999014039.USD","SG9999014021.USD","BK4588","IE00B3QW5Z07.USD","NDAQ","LU2210150020.SGD","LU2210149790.SGD","BK4139","IE00BKPKM429.USD","LU2095319765.USD","SG9999014005.SGD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654032570","title":"Veraxa Biotech Shareholders Approve All Proposals at Extraordinary General Meeting, Strengthening Strategic Flexibility for Future Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2654032570","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654032570?lang=en_us&edition=fundamental","pubTime":"2026-07-25 04:05","pubTimestamp":1784923500,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nTUA8DP80B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654039603","title":"VERAXA Biotech AG (NASDAQ: VRXA) Appoints Christoph Erkel as Chief Scientific Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2654039603","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654039603?lang=en_us&edition=fundamental","pubTime":"2026-07-25 01:00","pubTimestamp":1784912408,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, July 24th, 2026, FinanceWire VERAXA Biotech (NASDAQ:VRXA) announced the appointment of Christoph Erkel, Ph.D., a...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-ag-nasdaq-vrxa-appoints-christoph-erkel-as-chief-scientific-officer?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-ag-nasdaq-vrxa-appoints-christoph-erkel-as-chief-scientific-officer?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","IYW","TECS","BK4139","VRXA","BK4581","JEPQ","NDX","TQQQ","BK4210",".IXIC","QQQ","GPIQ","QQQJ","SQQQ","QQQY","QYLG","SILJ","SLVR","NQmain","AG","ONEQ","TQQY","QQQE","QDTE","BK4585","NVIW.SI","QLD","SLVX","QQQA","XBI","PSQ","MNQmain","SLJY","FTEC","QQQM","QID"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653017724","title":"VERAXA Biotech (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany","url":"https://stock-news.laohu8.com/highlight/detail?id=2653017724","media":"TIPRANKS","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653017724?lang=en_us&edition=fundamental","pubTime":"2026-07-24 00:30","pubTimestamp":1784824207,"startTime":"0","endTime":"0","summary":"Austin, Texas, United States, July 23rd, 2026, FinanceWire The company has received Scientific Advice from Germany’s Paul-Ehrlich-Institute (...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-bitacr-tce-development-with-positive-regulatory-feedback-from-germany?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/veraxa-biotech-nasdaq-vrxa-advances-bitacr-tce-development-with-positive-regulatory-feedback-from-germany?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONEQ","JEPQ","BK4585","R","TQQY","BK4022","QQQE","QDTE","QQQY","QQQA","NDX","NQmain","SQQQ","BK4232","GPIQ","VRXA","XBI","NVIW.SI","TECS","PSQ","MNQmain","IYW","QQQM",".IXIC","BK4588","QID","QYLG","QQQ","BK4581","QLD","BK4139","TQQQ","FTEC","QQQJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653774107","title":"Veraxa Biotech Names Christoph Erkel Chief Scientific Officer, Succeeding Rick Austin","url":"https://stock-news.laohu8.com/highlight/detail?id=2653774107","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653774107?lang=en_us&edition=fundamental","pubTime":"2026-07-23 19:02","pubTimestamp":1784804567,"startTime":"0","endTime":"0","summary":"Veraxa Biotech names Christoph Erkel chief scientific officer, succeeding Rick AustinVeraxa Biotech named Christoph Erkel chief scientific officer, effective immediately, to drive development of its B","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL6Sv8GL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","LU0314104364.USD","BCDF","IE00BKPKM429.USD","IE00BN0W2V16.EUR","LU2210149790.SGD","IE00B64PRP62.GBP","LU2210150020.SGD","SG9999014005.SGD","LU2095319765.USD","VRXA","SG9999014021.USD","IE00BGHQF748.EUR","NDAQ","BK4139","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","BK4585","BK4588","IE00B3QW5Z07.USD","SG9999014039.USD","SG9999014013.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653741470","title":"Veraxa Biotech Appoints Christoph Erkel as Chief Scientific Officer to Advance Bitac® Technology Platforms and Portfolio","url":"https://stock-news.laohu8.com/highlight/detail?id=2653741470","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653741470?lang=en_us&edition=fundamental","pubTime":"2026-07-23 19:00","pubTimestamp":1784804401,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nTUA9W6BWL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652297746","title":"Veraxa Biotech Receives PEI Scientific Advice on Bitac-tce Development Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2652297746","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652297746?lang=en_us&edition=fundamental","pubTime":"2026-07-20 19:01","pubTimestamp":1784545318,"startTime":"0","endTime":"0","summary":"Veraxa Biotech receives PEI scientific advice on BiTAC-TCE development planVeraxa Biotech received Scientific Advice from Germany’s Paul-Ehrlich-Institute on the biology and non-clinical development p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nNDL9D96jD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCDF","BK4588","SG9999014039.USD","IE00BN0W2W23.USD","IE00BGHQF748.EUR","IE00B64PRP62.GBP","IE00BN0W2T93.GBP","SG9999014013.SGD","SG9999014021.USD","BK4112","IE00BN0W2V16.EUR","VRXA","LU2210149790.SGD","IE00BKPKM429.USD","NDAQ","LU2210150020.SGD","BK4139","LU2095319765.USD","SG9999014005.SGD","BK4585","IE00B3QW5Z07.USD","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652297476","title":"Veraxa Biotech Announces Regulatory Progress with Its Bitac®-tce Development Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2652297476","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652297476?lang=en_us&edition=fundamental","pubTime":"2026-07-20 19:00","pubTimestamp":1784545200,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260720:nTUABZVG5Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["VRXA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652297045","title":"VERAXA Biotech Announces Regulatory Progress with its BiTAC®-TCE Development Plan","url":"https://stock-news.laohu8.com/highlight/detail?id=2652297045","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2652297045?lang=en_us&edition=fundamental","pubTime":"2026-07-20 19:00","pubTimestamp":1784545200,"startTime":"0","endTime":"0","summary":"Scientific Advice from the German Regulatory Authority supports the biological rationale and proposed development approach for VERAXA's BiTAC-TCE technology and product candidate, providing an initial","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/20/3329623/0/en/VERAXA-Biotech-Announces-Regulatory-Progress-with-its-BiTAC-TCE-Development-Plan.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4581","BK4588","BK4097","VRXA","BK4585","PRGS","XBI","LU2065732104.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":62,"code":"91000000","status":"200"}]}}